{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:45:37Z","timestamp":1784547937840,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003196","name":"ministero della salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2018-2021"],"award-info":[{"award-number":["Ricerca Corrente 2018-2021"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"fondazione umberto veronesi","doi-asserted-by":"publisher","award":["Young Investigator Fellowship"],"award-info":[{"award-number":["Young Investigator Fellowship"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00432-021-03811-3","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T16:10:51Z","timestamp":1633018251000},"page":"2529-2538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Vitiligo-like leukoderma\u00a0as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients"],"prefix":"10.1007","volume":"148","author":[{"given":"Sofia","family":"Verkhovskaia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Di Pietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Mastroeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luigia","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Abeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Morese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"D\u2019Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"De Galitiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5991-8914","authenticated-orcid":false,"given":"Cristina Maria","family":"Failla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"3811_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40264-019-00875-6","volume":"43","author":"S Babai","year":"2020","unstructured":"Babai S, Voisin AL, Bertin C et al (2020) Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: a retrospective cohort study. Drug Saf 43:111\u2013117. https:\/\/doi.org\/10.1007\/s40264-019-00875-6","journal-title":"Drug Saf"},{"key":"3811_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","volume":"60","author":"VR Belum","year":"2016","unstructured":"Belum VR, Benhuri B, Postow MA et al (2016) Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12\u201325. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.010","journal-title":"Eur J Cancer"},{"key":"3811_CR4","doi-asserted-by":"crossref","unstructured":"Barnhill RL, Piepkorn M, Busam KJ  (2004) Melanocytes. In: Pathology of melanocytic nevi and malignant melanoma Springer: New York, pp 1\u201310","DOI":"10.1007\/978-0-387-21619-5_1"},{"key":"3811_CR3","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","volume":"172","author":"A Breslow","year":"1970","unstructured":"Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902\u2013908. https:\/\/doi.org\/10.1097\/00000658-197011000-00017","journal-title":"Ann Surg"},{"key":"3811_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/esmoopen-2018-000442","volume":"4","author":"R B\u00fcttner","year":"2019","unstructured":"B\u00fcttner R, Longshore JW, L\u00f3pez-R\u00edos F et al (2019) Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open 4:e000442","journal-title":"ESMO Open"},{"key":"3811_CR6","unstructured":"Cancer Institute N (2017) Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"3811_CR7","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1158\/1078-0432.CCR-16-0903","volume":"22","author":"RM Chabanon","year":"2016","unstructured":"Chabanon RM, Pedrero M, Lefebvre C et al (2016) Mutational landscape and sensitivity to immune checkpoint blockers. Clin Cancer Res 22:4309\u20134321","journal-title":"Clin Cancer Res"},{"key":"3811_CR8","first-page":"705","volume":"29","author":"WH Clark","year":"1969","unstructured":"Clark WH, From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705\u2013727","journal-title":"Cancer Res"},{"key":"3811_CR9","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","volume":"81","author":"WH Clark","year":"1989","unstructured":"Clark WH, Elder DE, Guerry D et al (1989) Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81:1893\u20131904. https:\/\/doi.org\/10.1093\/jnci\/81.24.1893","journal-title":"J Natl Cancer Inst"},{"key":"3811_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/0470011815.b2a10019","author":"CD Corcoran","year":"2005","unstructured":"Corcoran CD, Senchaudhuri P, Mehta CR, Patel NR (2005) Exact inference for categorical data. Encycl Biostat. https:\/\/doi.org\/10.1002\/0470011815.b2a10019","journal-title":"Encycl Biostat"},{"key":"3811_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.seminoncol.2019.10.003","volume":"46","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Buti S, Agostinelli V, Bersanelli M (2019) A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Semin Oncol 46:362\u2013371","journal-title":"Semin Oncol"},{"key":"3811_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s13046-019-1426-2","volume":"38","author":"AM Di Giacomo","year":"2019","unstructured":"Di Giacomo AM, Valente M, Cerase A et al (2019) Immunotherapy of brain metastases: breaking a \u201cdogma.\u201d J Exp Clin Cancer Res 38:419","journal-title":"J Exp Clin Cancer Res"},{"key":"3811_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2340\/00015555-3355","volume":"100","author":"F Dimitriou","year":"2020","unstructured":"Dimitriou F, Mangana J, Dummer R (2020) Hair depigmentation and hair loss in advanced melanoma treated with combined immunotherapy and targeted therapy. Acta Derm Venereol 100:1\u20132. https:\/\/doi.org\/10.2340\/00015555-3355","journal-title":"Acta Derm Venereol"},{"key":"3811_CR14","doi-asserted-by":"publisher","first-page":"9522","DOI":"10.1200\/jco.2018.36.15_suppl.9522","volume":"36","author":"B Dreno","year":"2018","unstructured":"Dreno B, Ascierto PA, McArthur GA et al (2018) Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAF V600 mutation\u2013positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study. J Clin Oncol 36:9522\u20139522. https:\/\/doi.org\/10.1200\/jco.2018.36.15_suppl.9522","journal-title":"J Clin Oncol"},{"key":"3811_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"3811_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225731","author":"CM Failla","year":"2019","unstructured":"Failla CM, Carbone ML, Fortes C et al (2019) Melanoma and vitiligo: in good company. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20225731","journal-title":"Int J Mol Sci"},{"key":"3811_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2217\/imt-2019-0206","volume":"12","author":"T Gambichler","year":"2020","unstructured":"Gambichler T, Seifert C, Lehmann M et al (2020) Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. Immunotherapy 12:439\u2013444. https:\/\/doi.org\/10.2217\/imt-2019-0206","journal-title":"Immunotherapy"},{"key":"3811_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","volume":"25","author":"JE Gershenwald","year":"2018","unstructured":"Gershenwald JE, Scolyer RA (2018) Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol 25:2105\u20132110","journal-title":"Ann Surg Oncol"},{"key":"3811_CR19","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16:2598\u20132608. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0386","journal-title":"Mol Cancer Ther"},{"key":"3811_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100064","volume":"6","author":"M Guida","year":"2021","unstructured":"Guida M, Strippoli S, Maule M et al (2021) Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. ESMO Open 6:100064. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100064","journal-title":"ESMO Open"},{"key":"3811_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua C, Boussemart L, Mateus C et al (2016) Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 152:45\u201351. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2707","journal-title":"JAMA Dermatol"},{"key":"3811_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/CMR.0000000000000518","volume":"29","author":"SJE Hwang","year":"2019","unstructured":"Hwang SJE, Park JJW, Wakade D et al (2019) Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-Associated protein 4 therapy use in patients with metastatic melanoma. Melanoma Res 29:172\u2013177. https:\/\/doi.org\/10.1097\/CMR.0000000000000518","journal-title":"Melanoma Res"},{"key":"3811_CR23","doi-asserted-by":"publisher","unstructured":"Keung EZ, & Gershenwald JE, (2020) Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma, J. Natl. Cancer Inst\n 112(9):875\u2013885. https:\/\/doi.org\/10.1093\/jnci\/djaa012","DOI":"10.1093\/jnci\/djaa012"},{"key":"3811_CR24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL (2016) Sex differences in immune responses. Nat Rev Immunol 16:626\u2013638","journal-title":"Nat Rev Immunol"},{"key":"3811_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/nejmoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23\u201334. https:\/\/doi.org\/10.1056\/nejmoa1504030","journal-title":"N Engl J Med"},{"key":"3811_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/JLB.MR0618-241RR","volume":"105","author":"RA Le\u00f3n-Letelier","year":"2019","unstructured":"Le\u00f3n-Letelier RA, Bonifaz LC, Fuentes-Panan\u00e1 EM (2019) OMIC signatures to understand cancer immunosurveillance and immunoediting: melanoma and immune cells interplay in immunotherapy. J Leukoc Biol 105:915\u2013933","journal-title":"J Leukoc Biol"},{"key":"3811_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2230.2005.01779.x","volume":"30","author":"CP Mason","year":"2005","unstructured":"Mason CP, Gawkrodger DJ (2005) Vitiligo presentation in adults. Clin Exp Dermatol 30:344\u2013345. https:\/\/doi.org\/10.1111\/j.1365-2230.2005.01779.x","journal-title":"Clin Exp Dermatol"},{"key":"3811_CR28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.2340\/00015555-2035","volume":"95","author":"E Maverakis","year":"2015","unstructured":"Maverakis E, Cornelius LA, Bowen GM et al (2015) Metastatic melanoma\u2014a review of current and future treatment options. Acta Derm Venereol 95:516\u2013524","journal-title":"Acta Derm Venereol"},{"key":"3811_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura Y, Tanaka R, Asami Y et al (2017) Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol 44:117\u2013122. https:\/\/doi.org\/10.1111\/1346-8138.13520","journal-title":"J Dermatol"},{"key":"3811_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2302\/kjm.50.86","volume":"50","author":"G Parmiani","year":"2001","unstructured":"Parmiani G (2001) Melanoma antigens and their recognition by T cells. Keio J Med 50:86\u201390","journal-title":"Keio J Med"},{"key":"3811_CR31","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/nejmoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D et al (2019a) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381:626\u2013636. https:\/\/doi.org\/10.1056\/nejmoa1904059","journal-title":"N Engl J Med"},{"key":"3811_CR32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J et al (2019b) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 20:1239\u20131251. https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2","journal-title":"Lancet Oncol"},{"key":"3811_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I et al (2017) New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77:1\u201313. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.048","journal-title":"J Am Acad Dermatol"},{"key":"3811_CR34","doi-asserted-by":"publisher","first-page":"MMT30","DOI":"10.2217\/mmt-2019-0005","volume":"6","author":"E Simeone","year":"2019","unstructured":"Simeone E, Grimaldi AM, Festino L et al (2019) Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. Melanoma Manag 6:MMT30. https:\/\/doi.org\/10.2217\/mmt-2019-0005","journal-title":"Melanoma Manag"},{"key":"3811_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-19-1441","volume":"10","author":"KSM Smalley","year":"2020","unstructured":"Smalley KSM (2020) Two worlds collide: Unraveling the role of the immune system in Braf\u2013Mek inhibitor responses. Cancer Discov 10:176\u2013178. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-1441","journal-title":"Cancer Discov"},{"key":"3811_CR36","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/pcmr.12294","volume":"27","author":"HE Teulings","year":"2014","unstructured":"Teulings HE, Willemsen KJ, Glykofridis I et al (2014) The antibody response against MART-1 differs in patients with melanoma-associated leucoderma and vitiligo. Pigment Cell Melanoma Res 27:1086\u20131096. https:\/\/doi.org\/10.1111\/pcmr.12294","journal-title":"Pigment Cell Melanoma Res"},{"key":"3811_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33:773\u2013781. https:\/\/doi.org\/10.1200\/JCO.2014.57.4756","journal-title":"J Clin Oncol"},{"key":"3811_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, Hellmann MD, Hamid O et al (2017) Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res 5:417\u2013424. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0325","journal-title":"Cancer Immunol Res"},{"key":"3811_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/pcmr.12669","volume":"31","author":"CY Zhao","year":"2018","unstructured":"Zhao CY, Chou S, Liu RC, Fernandez-Pe\u00f1as P (2018) Naevus lightening in melanoma patients under BRAF\/MEK inhibitor combination therapy versus checkpoint immunotherapy: a histological and immunohistochemistry analysis. Pigment Cell Melanoma Res 31:341\u2013344. https:\/\/doi.org\/10.1111\/pcmr.12669","journal-title":"Pigment Cell Melanoma Res"},{"key":"3811_CR40","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41571-021-00508-x","volume":"18","author":"L Zitvogel","year":"2021","unstructured":"Zitvogel L, Perreault C, Finn OJ, Kroemer G (2021) Beneficial autoimmunity improves cancer prognosis. Nat Rev Clin Oncol 18:591\u2013602. https:\/\/doi.org\/10.1038\/s41571-021-00508-x","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03811-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03811-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03811-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T03:29:05Z","timestamp":1659583745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03811-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3811"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03811-3","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The protocol was approved by the IDI-IRCCS Institutional Ethical Committee (n. 510\/3, 2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}